Candel Therapeutics (CADL) to Release Quarterly Earnings on Thursday

Candel Therapeutics (NASDAQ:CADL) is anticipated to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Candel Therapeutics to post earnings of ($0.23) per share for the quarter.

Candel Therapeutics (NASDAQ:CADL) last announced its earnings results on Thursday, March 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.17). On average, analysts expect Candel Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Candel Therapeutics Stock Down 5.1 %

CADL opened at $8.22 on Wednesday. Candel Therapeutics has a 52 week low of $1.45 and a 52 week high of $14.60. The business has a fifty day simple moving average of $8.24 and a 200-day simple moving average of $7.06. The firm has a market cap of $266.95 million, a P/E ratio of -4.75 and a beta of -1.29.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on CADL shares. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 target price on shares of Candel Therapeutics in a research report on Friday, March 14th. Bank of America assumed coverage on shares of Candel Therapeutics in a report on Friday, February 7th. They issued a “buy” rating and a $15.00 price objective for the company. Citigroup initiated coverage on shares of Candel Therapeutics in a report on Thursday, February 20th. They set a “buy” rating and a $25.00 target price on the stock. Finally, Canaccord Genuity Group boosted their price target on shares of Candel Therapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th.

Insider Transactions at Candel Therapeutics

In other news, insider Charles Schoch sold 5,000 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $8.83, for a total value of $44,150.00. Following the sale, the insider now directly owns 38,038 shares in the company, valued at approximately $335,875.54. This trade represents a 11.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CTO Seshu Tyagarajan sold 14,322 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $7.22, for a total transaction of $103,404.84. Following the transaction, the chief technology officer now owns 96,790 shares of the company’s stock, valued at approximately $698,823.80. The trade was a 12.89 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 77,807 shares of company stock valued at $633,534. 41.60% of the stock is currently owned by corporate insiders.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.